News & updates

Milestones, programmes and the science behind accessible, scalable cancer monitoring — straight from the 2Strands newsroom.

2Strands Named One of LSI Asia 2026’s “Five Innovators to Watch”

Latest

8 July 2026

2Strands Named One of LSI Asia 2026’s “Five Innovators to Watch”

2Strands Biosciences presented ultra-sensitive ctDNA detection technology at LSI Asia 2026, sharing its approach to advancing cancer recurrence monitoring with investors, entrepreneurs, industry leaders and fellow MedTech innovators.

Read the full story →

3 February 2026

2Strands Secures Pre-Seed Funding to Accelerate Technology Development

2Strands Biosciences has secured pre-seed funding from Elev8.vc through its Ignite programme, alongside investments from angel investors.

October 2025

2Strands Strengthens Its Intellectual Property Portfolio with Two Patent Milestones

2Strands Biosciences has reached two important milestones in protecting its proprietary technology.

30 May 2025

2Strands Selected for MedTech Innovator’s 2025 Asia Pacific Accelerator

2Strands Biosciences was selected as one of 20 high-potential companies for MedTech Innovator’s 2025 Asia Pacific Accelerator, following a competitive selection process involving more than 550 applicants.

14 December 2024

2Strands Completes the NUS Medicine/22Health Accelerator Programme

2Strands Biosciences successfully completed the 13-week NUS Medicine/22Health Accelerator Programme, culminating in a Demo Day on 14 December 2024.

1 July 2024

2Strands Launches with Support from the Illumina for Startups Grant

2Strands Biosciences was launched with support from the Illumina for Startups Grant, which also provided one year of complimentary laboratory space and opportunities to collaborate with selected Illumina sites for proof-of-concept sequencing experiments.